2021 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management
H Ali, A Bacigalupo - American Journal of Hematology, 2021 - Wiley Online Library
The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR …
J Handlos Grauslund, MO Holmström… - Frontiers in …, 2021 - frontiersin.org
Background The calreticulin (CALR) exon 9 mutations that are identified in 20% of patients
with Philadelphia chromosome negative chronic myeloproliferative neoplasms (MPN) …
with Philadelphia chromosome negative chronic myeloproliferative neoplasms (MPN) …
[HTML][HTML] Association of factors influencing selection of upfront hematopoietic cell transplantation versus nontransplantation therapies in myelofibrosis
E Smith, J Huang, A Viswabandya, D Maze… - … and Cellular Therapy, 2021 - Elsevier
Despite the curative potential of allogeneic hematopoietic cell transplantation (HCT) for
myelofibrosis (MF), a significant number of patients with MF do not undergo HCT. Factors …
myelofibrosis (MF), a significant number of patients with MF do not undergo HCT. Factors …
Effect of pre‐transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis
S Cyriac, S Prem, MQ Salas, S Chen… - European Journal of …, 2021 - Wiley Online Library
Allogeneic hematopoeitic cell transplantation (allo‐HCT) is the only curative treatment for
myelofibrosis (MF). We evaluate the impact of various factors on survival outcomes post …
myelofibrosis (MF). We evaluate the impact of various factors on survival outcomes post …
Determination of cerebral blood flow velocity and microembolic signals in essential thrombocytosis by transcranial doppler ultrasonography
A Cinar, G Cetin, O Altintas Kadirhan… - Neurological …, 2021 - Taylor & Francis
Objectives The goal of treatment in essential thrombocytosis (ET) is to prevent vascular
complications such as thrombosis and hemorrhage. This study aimed to evaluate the risk of …
complications such as thrombosis and hemorrhage. This study aimed to evaluate the risk of …
[HTML][HTML] The role of navitoclax in myelofibrosis
S Pandravada, S Sandler - Cureus, 2021 - ncbi.nlm.nih.gov
Primary myelofibrosis (PMF) is the most aggressive type of chronic myeloproliferative
neoplasm, characterized by a disarray of hematopoietic stem cells and bone marrow …
neoplasm, characterized by a disarray of hematopoietic stem cells and bone marrow …
[HTML][HTML] Osteolytic bone lesions in patients with primary myelofibrosis: a systematic review
Abstract Background: Philadelphia negative Myeloproliferative neoplasms classically
characterized by excess production of terminal myeloid cells in the peripheral blood. Among …
characterized by excess production of terminal myeloid cells in the peripheral blood. Among …
Expression profile analysis reveals hub genes that are associated with immune system dysregulation in primary myelofibrosis
H Ma, J Liu, Z Li, H Xiong, Y Zhang, Y Song, J Lai - Hematology, 2021 - Taylor & Francis
Objection Primary myelofibrosis (PMF) is a familiar chronic myeloproliferative disease with
an unfavorable prognosis. The effect of infection on the prognosis of patients with PMF is …
an unfavorable prognosis. The effect of infection on the prognosis of patients with PMF is …
[图书][B] Myeloproliferative Neoplasms, An issue of hematology/oncology clinics of North America
J Mascarenhas, R Hoffman, R Levine, R Rampal - 2021 - books.google.com
This issue of Hematology/Oncology Clinics, guest edited by Drs. Ronald Hoffman, Ross
Levine, John Mascarenhas, and Raajit Rampal, is dedicated to Myeloproliferative …
Levine, John Mascarenhas, and Raajit Rampal, is dedicated to Myeloproliferative …
Advancing effective clinical trial designs for myelofibrosis
HE Kosiorek, AC Dueck - Hematology/Oncology Clinics, 2021 - hemonc.theclinics.com
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) associated with bone marrow
fibrosis, cytopenias, constitutional symptoms, hepatosplenomegaly, and/or extramedullary …
fibrosis, cytopenias, constitutional symptoms, hepatosplenomegaly, and/or extramedullary …